521 related articles for article (PubMed ID: 23433458)
21. MLK3 promotes metabolic dysfunction induced by saturated fatty acid-enriched diet.
Gadang V; Kohli R; Myronovych A; Hui DY; Perez-Tilve D; Jaeschke A
Am J Physiol Endocrinol Metab; 2013 Aug; 305(4):E549-56. PubMed ID: 23860122
[TBL] [Abstract][Full Text] [Related]
22. Amelioration of Metabolic Syndrome-Associated Cognitive Impairments in Mice via a Reduction in Dietary Fat Content or Infusion of Non-Diabetic Plasma.
Johnson LA; Zuloaga KL; Kugelman TL; Mader KS; Morré JT; Zuloaga DG; Weber S; Marzulla T; Mulford A; Button D; Lindner JR; Alkayed NJ; Stevens JF; Raber J
EBioMedicine; 2016 Jan; 3():26-42. PubMed ID: 26870815
[TBL] [Abstract][Full Text] [Related]
23. [Metabolic fatty liver diseases: hepatic consequences of the metabolic syndrome].
Anty R; Gual P; Huet PM; Marchand-Brustel YL; Tran A
Gastroenterol Clin Biol; 2007 Dec; 31(12):1127-34. PubMed ID: 18176372
[TBL] [Abstract][Full Text] [Related]
24. Obesity, Metabolic Syndrome and the Risk of Microvascular Complications in Patients with Diabetes mellitus.
Katsiki N; Anagnostis P; Kotsa K; Goulis DG; Mikhailidis DP
Curr Pharm Des; 2019; 25(18):2051-2059. PubMed ID: 31298151
[TBL] [Abstract][Full Text] [Related]
25. Role of inflammation in nonalcoholic steatohepatitis.
Choi S; Diehl AM
Curr Opin Gastroenterol; 2005 Nov; 21(6):702-7. PubMed ID: 16220049
[TBL] [Abstract][Full Text] [Related]
26. Cytokines and inflammation in adipogenesis: an updated review.
Jiang N; Li Y; Shu T; Wang J
Front Med; 2019 Jun; 13(3):314-329. PubMed ID: 30066061
[TBL] [Abstract][Full Text] [Related]
27. Innate immune activation in obesity.
Lumeng CN
Mol Aspects Med; 2013 Feb; 34(1):12-29. PubMed ID: 23068074
[TBL] [Abstract][Full Text] [Related]
28. Arachidonic Acid Metabolites in Cardiovascular and Metabolic Diseases.
Sonnweber T; Pizzini A; Nairz M; Weiss G; Tancevski I
Int J Mol Sci; 2018 Oct; 19(11):. PubMed ID: 30360467
[TBL] [Abstract][Full Text] [Related]
29. Metabolic syndrome is an inflammatory disorder: A conspiracy between adipose tissue and phagocytes.
Reddy P; Lent-Schochet D; Ramakrishnan N; McLaughlin M; Jialal I
Clin Chim Acta; 2019 Sep; 496():35-44. PubMed ID: 31229566
[TBL] [Abstract][Full Text] [Related]
30. Intestinal Inflammation Does Not Predict Nonalcoholic Fatty Liver Disease Severity in Inflammatory Bowel Disease Patients.
Carr RM; Patel A; Bownik H; Oranu A; Kerner C; Praestgaard A; Forde KA; Reddy KR; Lichtenstein GR
Dig Dis Sci; 2017 May; 62(5):1354-1361. PubMed ID: 28265826
[TBL] [Abstract][Full Text] [Related]
31. Soft drinks consumption and nonalcoholic fatty liver disease.
Nseir W; Nassar F; Assy N
World J Gastroenterol; 2010 Jun; 16(21):2579-88. PubMed ID: 20518077
[TBL] [Abstract][Full Text] [Related]
32. What about non-alcoholic fatty liver disease as a new criterion to define metabolic syndrome?
Tarantino G; Finelli C
World J Gastroenterol; 2013 Jun; 19(22):3375-84. PubMed ID: 23801829
[TBL] [Abstract][Full Text] [Related]
33. Nonalcoholic fatty liver disease: hepatic manifestation of obesity and the metabolic syndrome.
Boppidi H; Daram SR
Postgrad Med; 2008 Jul; 120(2):E01-7. PubMed ID: 18654060
[TBL] [Abstract][Full Text] [Related]
34. microRNAs as a new mechanism regulating adipose tissue inflammation in obesity and as a novel therapeutic strategy in the metabolic syndrome.
Ge Q; Brichard S; Yi X; Li Q
J Immunol Res; 2014; 2014():987285. PubMed ID: 24741638
[TBL] [Abstract][Full Text] [Related]
35. Preventive effect of geniposide on metabolic disease status in spontaneously obese type 2 diabetic mice and free fatty acid-treated HepG2 cells.
Kojima K; Shimada T; Nagareda Y; Watanabe M; Ishizaki J; Sai Y; Miyamoto K; Aburada M
Biol Pharm Bull; 2011; 34(10):1613-8. PubMed ID: 21963504
[TBL] [Abstract][Full Text] [Related]
36. The effect of increasing body mass index on cardio-metabolic risk and biomarkers of oxidative stress and inflammation in nascent metabolic syndrome.
Pahwa R; Adams-Huet B; Jialal I
J Diabetes Complications; 2017 May; 31(5):810-813. PubMed ID: 28285929
[TBL] [Abstract][Full Text] [Related]
37. The Influence of Epicardial Fat and Nonalcoholic Fatty Liver Disease on Heart Rate Recovery in Metabolic Syndrome.
Cho KI; Jo EA; Cho SH; Kim BH
Metab Syndr Relat Disord; 2017 Jun; 15(5):226-232. PubMed ID: 28346857
[TBL] [Abstract][Full Text] [Related]
38. GLUT4 content decreases along with insulin resistance and high levels of inflammatory markers in rats with metabolic syndrome.
Leguisamo NM; Lehnen AM; Machado UF; Okamoto MM; Markoski MM; Pinto GH; Schaan BD
Cardiovasc Diabetol; 2012 Aug; 11():100. PubMed ID: 22897936
[TBL] [Abstract][Full Text] [Related]
39. Metabolic syndrome and biochemical changes among non-alcoholic fatty liver disease patients attending a tertiary care hospital of Nepal.
Pardhe BD; Shakya S; Bhetwal A; Mathias J; Khanal PR; Pandit R; Shakya J; Joshi HO; Marahatta SB
BMC Gastroenterol; 2018 Jul; 18(1):109. PubMed ID: 29980170
[TBL] [Abstract][Full Text] [Related]
40. An Overview of Novel Dietary Supplements and Food Ingredients in Patients with Metabolic Syndrome and Non-Alcoholic Fatty Liver Disease.
Silva Figueiredo P; Inada AC; Ribeiro Fernandes M; Granja Arakaki D; Freitas KC; Avellaneda Guimarães RC; Aragão do Nascimento V; Aiko Hiane P
Molecules; 2018 Apr; 23(4):. PubMed ID: 29641459
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
